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Abstract
This review reports main progresses in various pediatric issues published in Italian Journal of Pediatrics and in
international journals in 2016. New insights in clinical features or complications of several disorders may be useful
for our better understanding. They comprise severe asthma, changing features of lupus erythematosus from birth to
adolescence, celiac disease, functional gastrointestinal disorders, Moebius syndrome, recurrent pneumonia. Risk
factors for congenital heart defects, Kawasaki disease have been widely investigated. New diagnostic tools are
available for ascertaining brucellosis, celiac disease and viral infections. The usefulness of aCGH as first-tier test is
confirmed in patients with neurodevelopmental disorders. Novel information have been provided on the safety of
milk for infants. Recent advances in the treatment of common disorders, including neonatal respiratory distress
syndrome, hypo-glycemia in newborns, atopic dermatitis, constipation, cyclic vomiting syndrome, nephrotic
syndrome, diabetes mellitus, regurgitation, short stature, secretions in children with cerebral palsy have been
reported. Antipyretics treatment has been updated by national guidelines and studies have excluded side effects
(e.g. asthma risk during acetaminophen therapy). Vaccinations are a painful event and several options are reported
to prevent this pain. Adverse effects due to metabolic abnormalities are reported for second generation
antipsychotic drugs.
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Background
Several papers have been recently published that can
potentially alter traditional approach of many diseases in
childhood. In this review, we focus on some of the new
key findings in allergy, autoimmune diseases, cardiology,
endocrinology, gastroenterology, infectious diseases,
neonatology, nephrology, neurology, nutrition, pulmo-
nology in childhood. We mainly have summarized articles
issued in Italian Journal of Pediatrics in 2016. A choice of
valuable information that appeared in international jour-
nals have also been covered and placed in context.
Review
Allergy. 1-Management of atopic dermatitis; 2-severe
asthma; 3-role of vitamin D in asthma
Asthma [1] and atopic dermatitis (AD) are common
atopic conditions that can be successfully controlled by
providing patients instructions on the diseases and by
explaining how to use reliever and preventive treat-
ments. A small proportion, probably less than 5%, of
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asthmatic children suffers from severe asthma. This
subset of asthmatics is difficult to treat and children
have more frequent hospitalizations for asthma, emer-
gency department visits for asthma, exercise-induced
symptoms, and receive more commonly systemic ste-
roids for exacerbations than non-severe asthmatics [2].
Quality of life is reduced. New insights in characteristics
of children with severe asthma which present different
phenotypes and endotypes [3] may provide a basis for
improving treatment. Airflow obstruction is a criterion
for defining asthma severity [4]. Montella et al. [2]
confirmed that severe asthmatics have impaired lung
function. However, they found forced expiratory volume
in 1 second was normal in approximately half the cases.
Accordingly, it has been shown that lung function did
often not correlate with asthmatic symptoms [5] or oxi-
dative stress [6]. Among risk factors, Montella et al. [2]
reported that severe asthma was also associated with
food sensitization but not with environmental exposure,
comorbidities, medication adherence, exhaled nitric
oxide levels, blood eosinophils and serum IgE levels.
Asthmatics with vitamin D deficiency have been found
to be not at risk for severe asthma [7]. However, the
presence of asthma was strongly associated with low
vitamin D levels in serum [7, 8]. Treatment of asthma
with vitamin D in schoolchildren was the aim of a
randomized, double-blind, placebo-controlled trial [9]. It
has been found that 800 IU/day of vitamin D3
supplementation for 2 months significantly improved
childhood asthma control test score and reduced num-
ber of asthmatic children with a peak expiratory flow
rate < 80% predicted. In contrast, an initial bolus of
vitamin D (100,000 IU once), followed by 4000 IU/die
for 7 months did not show to be of benefit in asthmatics
[10]. Tachimoto et al. [9] suggested that vitamin D
supplementation at low dose may ameliorate the control
of asthma in childhood.
Regarding AD, this year has been issued the Consensus
on clinical management by the Italian Society of Pediatric
Allergology and Immunology and the Italian Society of
Pediatric Dermatology [11]. Authors recommend skin
emollients and bathing in lukewarm water with non-soap
cleansers and synthetic detergents with no preservatives
and perfumes to maintain the epidermal barrier function.
They pointed out that topical corticosteroids are the first-
line therapy. In areas where relapsing is frequent, control
of disease improves by applying topical corticosteroids
twice a week. The document emphasizes that topical cal-
cineurin inhibitors are a second-line option for acute
flares when topical corticosteroids are not effective, con-
traindicated or induce side-effects. In chronic AD, they
can be used as continuous or intermittent long-term treat-
ment for 12 months, then a reassessment is warranted.
Topical calcineurin inhibitors should not be used in young
children less than 2 years old, congenital or acquired im-
munodeficiency, skin infections, eroded and/or exuding
lesions, sun exposure. Wet wrap therapy or phototherapy
should be considered when lesions are resistant to topical
anti-inflammatory treatment. Several systemic treatments
are used as a third-line option. Systemic corticosteroids
can be used for short-term treatment of severe AD,
while the long-term use is limited by side-effects and
exacerbation after cessation of treatment. Systemic
immunosuppressants including ciclosporin, azathio-
prine, methotrexate are used off-label apart from
ciclosporin, in some European countries [12]. Optimal
dose and length of treatment of azathioprine and
methotrexate are unclear. Among other therapies,
first-generation antihistamines may be used when
nocturnal sedation is a desirable effect. Allergen im-
munotherapy to mites may be of benefit in a sub-
group of patients [13].
Autoimmune diseases. Lupus erythematosus during
childhood
Many studies have documented the changing features of
lupus erythematosus during childhood. Neonatal lupus
erythematosus (NLE) is an uncommon autoimmune dis-
ease characterized by cutaneous lupus lesions and/or
congenital heart block. It is due to maternal antinuclear
antibodies and extractable nuclear antigen antibodies.
These maternal autoantibodies against RNA protein
complex, Ro/SSA or SSB/La cross the placenta and
potentially lead to fetal tissue damage and the clinical
manifestations NLE. The cutaneous lesions may be
present at birth, but more often develop within the first
few weeks of life. Savino et al. [14] presented four cases
of cutaneous NLE, two females and two males, who had
no signs or symptoms at birth and they developed cuta-
neous lesions from 2 days to 3 months after delivery.
Mothers were positive for Ro/SSA and La/SSB in all the
cases and one of them also presented a positivity of anti-
CCP and Rheumatoid factor, with a reduction in C4.
These cases confirmed that NLE is a condition usually
benign and self-limited. Its evolution is the spontaneous
regression of the lesions within six months without
progression to systemic lupus erythematosus (SLE).
Furthermore, it is common to see that autoimmunity in
the mother is not detected until the birth of a child with
NLE. Childhood-onset SLE is a multisystem, auto-
immune disease, beginning before the age of 18 years
that may affect any organ. Children are known to have a
more severe disease course. Approximately one third of
children will present with life-threatening, “non-clas-
sical” clinical manifestations that are not included in the
revised American College of Rheumatology classification
criteria. Fatemi et al. [15] retrospectively studied 188
children, 33 were diagnosed with SLE when they were
Caffarelli et al. Italian Journal of Pediatrics  (2017) 43:80 Page 2 of 16
<12 years, 149 (81.9%) with SLE at 12–18 years of age, 6
patients were lost to follow-up. Both groups had similar
clinical manifestations and laboratory findings. During
follow-up, 20 children died. The SLE group aged 12–
18 years presented higher rates of deaths (13/20, 65%),
followed by those aged >18 years (6/20, 30%) and those
younger than 12 years (1/20, 5%). 50% of deaths oc-
curred during the first year after SLE onset and only
25% after the first 5 years. The most common cause of
death was lupus nephritis and infections (10 patients,
50% and 7 patients, 35% of all deaths) with a significant
pattern of death: 53% of deaths during the first 5 years
were due to infections, but all deaths after the first
5 years were due to lupus nephritis (P = 0.04). The over-
all 5, 10, 15 and 20 years survival rates after SLE onset
were 91%, 87%, 85% and 79%, respectively. Age of SLE
onset had no association with survival but having
hematuria or pleurisy at the time of SLE onset had a
negative effect on survival in multivariate analysis. The
survival rate of SLE children seems to be comparable
throughout the world.
Low vitamin D serum levels are common in patients
with SLE and seem to correlate with higher disease ac-
tivity. Lima et al. [16] conducted a randomized, double-
blind, placebo-controlled, 24-week trial to investigate the
effects of vitamin D supplementation on disease activity
and fatigue in juvenile-onset SLE. 40 female patients
were randomized into 2 parallel groups to receive oral
cholecalciferol of 50,000 IU/week (SLE-VitD group) or
identical placebo tablets for 6 months (SLE-PL group).
Fatigue and disease activity were assessed using the Kids
Fatigue Severity Scale and the Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI) and the
European Consensus Lupus Activity Measurement
(ECLAM) respectively. Demographic characteristics,
clinical and laboratory parameters, medication use, in-
cluding mean daily dose of glucocorticoids and the use
of immunosuppressive drugs and adherence to vitamin
D supplementation were assessed at baseline, after
3 months and at the end of supplementation. At base-
line, the mean 25(OH)D serum levels were similar in the
2 groups and 95% of all juvenile-onset SLE patients had
a vitamin D insufficiency (25(OH)D < 30 ng/ml). After
12 months, values above 30 ng/ml were found in 70% of
patients in SLE-VitD group while in 0% in SLE-PL
group. A significant difference in disease activity scores
(SLEDAI and ECLAM) was found at 6 months com-
pared to baseline in the juvenile-onset SLE-vitamin D
group compared to the SLE-PL group (improvement in
SLEDAI scores p = 0.011 and in ECLAM: p = 0.006). At
the end of the study, SLE-VitD group had a better global
score for fatigue than the placebo group (P = 0.012) and
this improvement was more significant in social life fa-
tigue score (P = 0.008). This study showed that routine
screening for vitamin D deficiency and its prompt
treatment in patients with SLE is recommended and
may decrease disease activity scores and fatigue.
Cardiology. 1-Risk factors for congenital heart defects;
2-origin of Kawasaki disease; 3-hypertension
Recent studies about congenital and acquired heart
defects, mainly Kawasaki disease (KD), in childhood
have evoked a great interest. Maternal alcohol consump-
tion is associated with the fetal-alcohol syndrome that
can provoke different degrees of embryopathy, ranging
from minor to severe symptoms. Furthermore, it can be
related with neurobehavioral disorders listed in the
Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition (DSM-5) as a condition for further study
[17]. Children and adolescents prenatally exposed to al-
cohol may have brain damage with functional impair-
ment of neurocognition, self-regulation, and adaptive
functioning [18]. Up to one-third of individuals affected
by fetal-alcohol syndrome have congenital heart defects
(CHDs), e.g. conotruncal defects, left ventricular outflow
track defects, septal defects. Several risk factors of CHDs
have been recognized such as chromosomal abnormal-
ities, maternal illnesses, prenatal exposures to terato-
gens. Several studies have assessed the relation between
CHDs and prenatal alcohol consumption, reporting dif-
ferent results. Therefore, it is worthwhile that a meta-
analysis by Wen et al. [19] found no association between
maternal alcohol consumption during pregnancy and the
risk of CHDs. These findings confirmed conclusions of a
previous systematic review [20]. The major cause of
acquired heart disease in developed countries is
represented by coronary artery abnormalities, that is the
main complication of KD. The etiology of KD remains
unknown though infection is considered one of the pre-
disposing factors. No infectious agent has been identified
as unique cause of KD. Independent risk factors for
coronary artery abnormalities include male gender,
serum albumin, erythrocyte sedimentation rate (ESR),
Mycoplasma pneumoniae (MP) infection, intravenous
immunoglobulin (IVIG) started after the 10th day of ill-
ness and IVIG non-responders [21]. A well-designed
prospective case-control study investigated the etiologic
role of MP in KD [22]. MP infections were found in 62/
450 KD patients and occurred in older populations and
with a higher rate of respiratory tract involvement. No
statistical difference in the incidence of coronary artery
lesion was observed between the MP+ and MP- KD pa-
tients. Lee et al. [23] also showed no difference in both
left and right coronary artery abnormalities of MP+ and
MP- KD patients by analyzing 12 KD patients and 42
controls. Overall, these findings suggest that other
factors different from MP should be investigated for the
onset of coronary lesions in KD. Primary hypertension
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represents a growing problem in children and adoles-
cence. Recent novelties in the field of prevention, diag-
nosis and treatment of hypertension in children were
considered by Strambi et al. [24]. Authors emphasized
that the definition of normal blood pressure values in
neonates are lacking [25]. However, it is advisable to use
results of the study by Dionne et al. [26] that provided
blood pressure values corresponding to different percen-
tiles at 15 days of age according to gestational age. In
pediatric age, diagnosis of hypertension is based on
repeated office measurements exceeding reference values
[24]. Ambulatory blood pressure monitoring can be
useful in children older than 10 years of age to clarify
critical issues, such as hypertension during hypersensi-
tivity reaction [27]), white coat hypertension, masked
hypertension, treatment efficacy, nocturnal drop [24].
Strambi et al. [24] considered also another key point that
is the positive effect of physical exercise on prevention
of primary hypertension by reducing overweight, inferior
quality of sleep and by maintaining sodium homeostasis
[28]. However, they [24] reported a list of isometric and
intensive sports that are not recommended in case of
stage 2 hypertension not pharmacologically controlled. It
must be also considered that diagnosis of hypertension
should not be neglected in athletic adolescents [29].
Endocrinology. 1- Staminal’s Research in prevention/
treatment of type 1 diabetes, 2-use of Omnitrope
A series of innovative papers have addressed key topics
such as management of diabetes and use of growth hor-
mone (GH) for short stature. Replacement of pancreatic
beta-cells represents an ideal treatment that could over-
come the difficulties to manage multi-injective insulin and
progressive worsen of diabetes [30]. Due to shortage of or-
gans and the inability of islet to be expanded ex vivo, this
therapy can be offered to a very limited number of pa-
tients. The advent of stem cells as renewable source of
cell-substitutes to replenish the beta-cell population, has
blurred the hype on islet transplantation. Unfortunately, a
cell source providing a robust response after differenti-
ation as embryonic stem cells (ESC), is not always consid-
ered safe because of transplant-related collateral effects
such as immune rejection or, worse, tumorigenesis. For
these reasons, scientists are focusing on various sources of
stem cells that possess less stemness potential compared
to ESC but are safer and free of ethical concerns, namely
adult stem cells. The pancreas itself is a promising source
for stem cells: duct cells, acinar cells and stem cell from
islets of Langerhans share the same embryological origin
of beta-cells; therefore, they are good candidates for the
de-differentiation and re-programming towards an insulin
producing phenotype. The obstacles to the extensive use
of this source are represented by the invasive collection
procedures, the scarcity of the stem cells, the difficulty in
isolating and expanding the culture in vitro [31]. The der-
ivation of insulin producing cells from hepatocytes (trans-
differentiation or lateral re-programming), which share
with beta-cells the same endodermic origin, showed
promising outcomes. However, even though these tissues
represent an abundant pool of reprogrammable cells, the
use of hepatocytes ex vivo is hampered by the shortage of
donors, poor in vitro expansion capacities, and rapid cell
de-differentiation. Mesenchymal stem cells (MSC) from
various tissues, pancreas included, are a widely accessible
source of insulin producing cells. The expectations on
MSC studies were nurtured by the abundance of cells, the
ease in isolation and in vitro expansion, and the promising
outcomes of diverse studies showing the differentiation
potential towards non-mesodermic lineages [32]. Stem
cells isolated from the amnion layer of placenta meet most
of the mentioned criteria and the adoption of hAECs in
cell therapy and regenerative medicine do not raise any
ethical concern. Even if at present there are no clinic-
ally approved treatments of diabetes based on the use
of stem cells, several therapeutic approaches have
already been evaluated or are being evaluated in clinical
trials [33].
Omnitrope® is a recombinant human GH approved for
the treatment of children with growth disorders associated
with short stature (e.g. GH deficiency, Turner syndrome,
chronic renal insufficiency). PAtients TReated with Omni-
trope® study assessed the safety and effectiveness of Omni-
trope® among 186 children diagnosed with conditions of
short stature requiring GH treatment [34]. Omnitrope®
was associated with improvement in height standard devi-
ation scores and height velocity standard deviation scores.
Adverse reactions were reported in 9.1% of patients and
two of these were considered serious (minimal increase in
a known residual craniopharyngioma, and gait disturb-
ance). However, conflicting data have been reported on
the risk of developing cancer in children treated with GH
[35]. Comparable results on Omnitrope® safety and effi-
cacy have been achieved in a multicenter, retrospective
follow-up study. A Spanish population with GH deficiency
showed adult height within the local normal ranges and
no adverse events during the GH therapy [36]. Consist-
ently, the use of Genotropin®, a biosimilar product, has
been studied in an open-label, multicenter, randomized
trial. After 4 years of treatment, 316 children with idio-
pathic short stature in all treatment regimens achieved
similar average height gains; however, the individualized
dosing regimen utilizing less GH reached an equivalent
height gain [37].
Gastroenterology. 1-Celiac disease screening and
manifestations; 2- functional gastrointestinal disorders
Celiac disease (CD) is an immune-mediated enteropathy
caused by permanent intolerance to gliadin and related
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proteins present in gluten among genetically susceptible
individuals. There has been an apparent increase in the in-
cidence of CD over the past 30 years [38]. It is unclear
whether the changing prevalence of reported cases of CD
is due to a real increase in the number of cases, enhanced
awareness of disease or more reliable serologic testing.
The definitive diagnosis of CD is based on typical changes
in the small intestine biopsy specimens. To screen individ-
uals for CD serum tTG-IgA and EMA IgA antibodies are
used. AGA determination has been necessary for children
younger than 18 months of age who frequently present
negative EMA and anti-tTG antibody results. Di Tola et
al. [39] assessed the role of fecal celiac intestinal antibody
tests in identifying CD patients. To this aim they com-
pared a spot stool sample obtained from twenty-five sera
EMA/anti-tTG positive CD patients and 12 sera EMA/
anti-tTG negative controls, while they were eating gluten.
They found that fecal IgA anti-tTG, IgA anti-DGP, IgA/
IgG anti-tTG/DGP, and IgA anti-actin antibodies levels in
CD patients were significantly higher in comparison with
those detected in healthy controls. Fecal IgA EMA were
found in 11 out of 25 (44.0%) CD patient but in none of
healthy volunteers (p = 0.0066). Conversely, EMA IgG,
anti-tTG IgG, and anti-DGP IgG were not detectable in
fecal supernatants neither from CD patients nor from
controls. These findings extended the celiac intestinal
antibody pattern to other antibodies detectable in fecal su-
pernatants but, for the small size of the sample, larger
studies are needed to assess the role of fecal antibody tests
in identifying CD patients, when serologic tests are nega-
tive. CD presents a wide range of both gastrointestinal
and non-gastrointestinal symptoms. Khatib et al. [40]
retrospectively evaluated clinical features in newly diag-
nosed children with CD. Among 165 subjects, the median
age at presentation was 10.7 ± 4.3 years. No patient was
less than 1 years of age. Abdominal pain was the most
common presenting feature (52.7% of patients), followed
by constipation (38.9%), diarrhea (31.1%), family history of
first-degree relative (28.1%), diabetes mellitus type 1
(22.2%), failure to thrive (21.8%), reflux (15.1%), vomiting
(14.5%), fatigue (9%), short stature (5.4%), thyroid disease
(5.4%), Down syndrome (4.8%). All the patients had posi-
tive tTG-IgA, except 2. They found no correlation be-
tween the serum tTG-IgA and Marsh score, this suggests
that tTG-IgA levels may not reflect the disease severity.
This study shows a change in CD clinical presentation: the
so-called classical symptoms of diarrhea, irritability and
weight loss were less frequent and children more com-
monly presented with abdominal pain and constipation.
This probably reflects rapid westernization leading to
changes in dietary habits and early exposure to gliadin
through highly processed foods. In conclusion, the possi-
bility of CD should be considered in any child presenting
with chronic abdominal pain and constipation.
Higher frequency of CD has been described among
patients with neurological diseases. Most case reports
suggest an association between autistic spectrum
disorders (ASDs) and CD or positive CD serologic test
results, but larger studies are contradictory. In a retro-
spective study, Calderoni et al. [41] evaluated CD preva-
lence in 382 children with ASDs. Overall, CD or positive
CD serology were detected in 10 of 382 children with
ASD, the mean age was 41 months (SD: 15.2; range: 20–
67). The authors compared these data to that found in
the general population, using the data from the survey
of Mustalahti et al. [42] which investigated the CD
prevalence in four European countries, including
Italy. They found a statistically significant difference
(p value = 0.0131) in the prevalence of CD cases in their
sample (2.62%; 95% CI:1.0–4.2) compared to the Italian
pediatric population (1.1%; 95% CI: 0.7–1.5) with an age-
range from 0 to 19 years. These findings indicate that an
association between ASD and CD cannot be excluded.
Neurological symptoms including ataxia, neuropathy,
vestibular dysfunction, seizures, migraine, and headache
are reported in 10%–22% of patients with CD [43].
Nenna et al. [44] aimed to determine the prevalence of
CD in children with recurrent headache, to detect any
relationship between them, to characterize the clinical
and epidemiological features and finally to investigate
the effects of the gluten free diet on headache in patients
with CD. They studied 883 subjects (481 females, median
age 9.8 years, range 3–19). In cases with positive serology
tests, duodenal biopsy was performed for confirmation of
CD. Of 883 patients with headache, 18 (2.04%) were
celiac. Among these, 7 children were already diagnosed as
celiac and were on a gluten free diet at the time of neuro-
logic evaluation, 11 children had positive serology tests
and underwent to duodenal biopsy that confirmed the
diagnosis of CD. Among the patients with a diagnosis
of CD, the most frequent type of headache was migraine
without aura (50%), followed by tension-type headache
and migraine with aura (38.9% and 11.1% respectively).
The duration of attack in 72.2% of children was 30 min –
4 h and most of patients had mild or moderate intensity
of headache. The prevalence of CD in children with head-
ache was significantly higher (2.04%, p = 0.034), than that
reported in Italian general population (1.2%) [45]. Head-
ache improved among all patients after gluten free diet.
These findings indicate that diagnostic tests for CD might
be useful in children with recurrent headache, especially
among non-responders to common therapies.
Recent studies also suggest that migraine may be
associated with other gastrointestinal disorders, includ-
ing irritable bowel syndrome, inflammatory bowel syn-
drome and functional gastrointestinal disorders (FGIDs).
Le Gal et al. [46] did a robust case-control study in the
emergency departments of four European hospitals to
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establish the prevalence of FGIDs in children and
adolescents with primary headaches and investigate a
possible relationship with migraine. They compared the
prevalence of ten FIGDs in three groups of patients aged
6–18 years (257 with migraine, 167 with tension-type
headache, and a control group of 648 headache-free in-
dividuals). Headaches were diagnosed by a neurologist
using the International Classification of Headache Disor-
ders and FGIDs by investigators masked to headache
diagnosis who used Rome III diagnostic criteria. They
found a significant association between the presence of
migraine and functional dyspepsia and abdominal mi-
graine. Furthermore, there was an inverse association
between migraine and functional constipation. No asso-
ciation was found between tension-type headache and
FGIDs. This study indicates a relationship between mi-
graine and FGIDs. This is probably due to a shared
pathophysiological mechanism of pain involving several
inflammatory mediators, such as serotonin, and calci-
tonin gene-related peptide.
FGIDs are highly prevalent in childhood and pose a
significant burden for the society, and affect the quality
of life of patients and their families. FGIDs comprise a
heterogeneous group of disorders with unclear patho-
physiology. They are among the most challenging disor-
ders to manage and many strategies, including
pharmacological, dietary, cognitive behaviors and alterna-
tive approaches have been evaluated for their treatment.
Salvatore et al. [47] systematically reviewed evidences on
the effects and clinical relevance of pharmacological ther-
apy in infants with FGIDs. They did not find improvement
of regurgitation by proton pump inhibitors, anti-H2 or
domperidone and they suggested considering alginate in
infant regurgitation when symptoms are severe, associated
with marked distress, and other non-pharmacological
measures failed. For cyclic vomiting syndrome, a migraine
variant characterized by recurrent, stereotypical episodes
of intense nausea and vomiting, separated by intervals of
wellness, they suggest intravenous infusion of fluids, onda-
setron, lorazepam and acid inhibitors during the acute
phase of vomiting. Several retrospective studies showed
efficacy of cyproheptadine, propanolol and pizotifen in
prophylaxis. In case of constipation [48], lactulose is rec-
ommended for infants younger than 6 months of age,
whereas in older infants and in children polyethylene gly-
col with or without electrolytes represents the first-line
therapy for both fecal disimpaction and maintenance. No
evidence of effectiveness of pharmacological treatment
were found for infant rumination syndrome, infant colic,
functional diarrhea and infant dyschezia.
However, Madani et al. [49] recently demonstrated a
good safety and efficacy profile in the use of cyprohepta-
dine, a first-generation antihistamine with a serotonin
antagonist effect, in children with FGIDs defined by
Rome III clinical criteria. Complete improvement of
symptoms was reported in 110 out of 151 patients (73%)
(complete improvement group: CIG), 41 (27%) has par-
tial or no improvement (improvement group/partial im-
provement group: NIG/PIG), it was completely effective
in 36/55 (65%) children with functional abdominal pain
and in 26/34 (76%) patients with functional dyspepsia.
The mean duration of treatment with cyproheptadine
was 8.91 months (range 1–48) in the CIG and 5.72
(range 1–26) in the NIG/PIG. Side effects were experi-
enced by 49/151 patients. A higher proportion was in
the NIG/PIG (41%, 20/49), presumptively for the higher
doses needed. Sleepiness and weight gain were the most
frequent adverse effects (19/151 (12%) and 15/151 (10%)
respectively. Logistic regression analysis showed that
lower the body weight, the higher were the odds of no
or partial improvement. This is probably due to lower
maturity of enterochromaffin cell receptors in the gut
epithelium, suggesting caution in the use of cyprohepta-
dine in children with low body weight. The single best
predictor of clinical improvement was body mass index.
Infectious diseases. 1-Brucellosis; 2-fever treatment;
3-pain in vaccination
Management, treatment and prevention of common and
uncommon infectious diseases have been explored last
year. Brucellosis is a serious public health problem that
brings about socioeconomic consequences in many
countries. The infection occurs in humans by ingestion
of animal milk or its products, by direct contact with in-
fected animals or inhalation of infectious aerosols,
resulting in acute or chronic disease with non-specific
symptoms, difficult to diagnose and treat. Up to 80% of
patients develop rheumatic problems with subsequent
functional impairment. Aktar et al. [50] conducted a
retrospective study in 64 children to evaluate the role of
inflammatory markers in the diagnosis of pediatric
Brucella arthritis (BA). The diagnosis of arthritis was
made on clinical symptoms (joint pain, restriction of
movement, and swelling), isolation of Brucella from
blood or synovial fluids and positive Brucella serology
test >1:160. White blood cell (WBC) count, neutrophil
count, lymphocyte count, hemoglobin (Hb), platelet
count (PLT), mean platelet volume (MPV), neutrophil to
lymphocyte ratio (NLR) and platelet to lymphocyte ratio
(PLR), C-reactive protein (CRP), ESR, agglutination
assay and culture for both blood and joint puncture.
They found a significantly difference in WBC, Hb, neu-
trophil count, lymphocyte count, PLT, MPV, NLR and
PLR values between the study and the control groups,
but no correlation was found between MPV, ESR and
CRP values. NLR, PLR and MPV mean values were
higher in patients with BA compared to the control
group (NLR 4.1 vs 1.4, p < 0.001; PLR 154 vs 106,
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p < 0.001; MPV 8.2 vs 7.3, p = 0.026). The most fre-
quently involved joint was ankle and the most used anti-
biotics were rifampicin plus sulfamethoxazole/
trimethoprim and gentamicin. Authors suggested the
use of NLR and PLR ratios as reliable inflammatory
markers in the diagnosis and follow-up of BA in
children.
Karaman et al. [51] retrospectively analyzed the
hematologic findings of 622 Turkish children, mean age
11.06 years (±4.3) with acute brucellosis. All cases had
direct contact with sick animals, sick family member or
consumption of unpasteurized dairy products from
farms where brucellosis had been already established.
Laboratory abnormalities were observed in 292 patients
(46.9%). The most frequent laboratory findings in
affected children included anemia (Hb <11 g/dL) in 178
(28.6%), thrombocytopenia (<150,000/mm3) in 100
(16%) and leukopenia (<4000/mm3) in 87 (13.9%) pa-
tients. Pancytopenia (Hb < 11 g/dL, PLT < 150,000/
mm3, WBC < 4000/mm3) was observed in 48 (7.7%)
children. The authors underlined the importance of es-
tablishing a prompt diagnosis of brucellosis in children
with clinical manifestations, anemia, leukopenia,
thrombocytopenia, or pancytopenia and positive
epidemiological data, especially in rural parts of the
country.
Current approaches for distinguishing bacterial from
viral causes of acute infections are unreliable and in-
accurate. No single biomarker distinguishes between
viral and bacterial etiologies in settings where all may be
involved. Van Houten et al. [52] aimed to assess the ac-
curacy of a novel host–response-based diagnostic assay,
ImmunoXpert, to distinguish bacterial infections from
viral infections compared with CRP and procalcitonin.
ImmunoXpert integrates the concentrations of three
biomarkers: tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL), interferon gamma induced
protein-10 (IP-10), and CRP. They conducted a pro-
spective, double-blind study and recruited children, aged
between 2 and 60 months, with fever without source or
lower respiratory tract infection, consecutively presented
at the emergency departments and pediatric wards. They
found that the combination of CRP, IP-10, and TRAIL
improved diagnostic ability to distinguish bacterial from
viral infections and may help in rational use of antibi-
otics in children.
In the last decade thanks to progress in molecular
technologies, newly discovered viruses have been identi-
fied. In this context, establishing a causal link between a
newly identified virus and the disease as well as an
association between mixed infections and an increase in
disease severity can be challenging. Cebey-López et al.
[53] conducted a prospective observational multicenter
study to analyze the relationship between viral or
bacterial co-infection detected by molecular methods,
and the clinical phenotype of children with lower tract
acute respiratory infections (LT-ARI). They enrolled two
independent patient groups, 204 children in Spain (main
group) and 97 children in the United Kingdom (replica-
tion group), under 14 years of age with a lower respira-
tory tract illness of sufficient severity to warrant
admission to hospital, and a virus identified on nasopha-
ryngeal swab or aspirate sample. Children presenting a
bacterial superinfection had more severe respiratory dis-
tress, a higher severity score, required significantly more
respiratory support and they had a longer hospital stay.
Conversely, the number of detected viruses did not cor-
relate with any markers of severity and did not influence
the outcome. In addition, patients who received the
pneumococcal vaccine had lower risk of being admitted
to pediatric intensive care unit and had less risk of re-
spiratory support requirement.
Regarding management of infectious diseases, causal
treatment and antipyretics are the most commonly used
drugs. The Italian Pediatric Society recently updated the
guidelines for management of fever in children [54]. It
highlighted that antipyretics should be administered or-
ally with the purpose to control the child’s discomfort.
Combined use of acetaminophen and ibuprofen is dis-
couraged. Antipyretics are not recommended to prevent
fever and local reactions in children undergoing vaccin-
ation, or febrile convulsions. Incorrect use of antipyretics
is associated with fever phobia phenomenon that
considers fever as health dangerous. According to a
Portuguese study, fear of fever has been shown to be
caused both by parents’ and healthcare professionals’ at-
titudes and beliefs [55]. A cross-sectional study analyzed
the appropriateness of antipyretic dosages in a popula-
tion of 1397 children with fever requiring a primary care
outpatient visit [56]. Acetaminophen was administered
for body temperature ≤ 38.4 °C in 74% of cases, with a
daily overdose (>90 mg/kg/day) in 24% of cases. Self-
medication was described in 60% of children, in all cases
acetaminophen was administered at temperature < 38 °C.
Self-prescription phenomena strictly related to the admin-
istration of high dosages of acetaminophen and was more
frequent in caregiver with a higher level of education.
Moreover, the intake of the drug as drops or syrup was as-
sociated with over dosage. Lubrano et al. [56] also empha-
sized the preventive role of the general practitioners in the
education for the right prescription and assumption of
acetaminophen in childhood.
Acetaminophen administration at standard as-needed
doses is considered safe. However, it has been suggested
that acetaminophen consumption may be associated
with increasing asthma exacerbations, leading some
physicians to avoid it in asthmatic children [57]. A
multicenter, prospective, randomized, double-blind
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trial showed no difference in the number of asthma
exacerbations, days with controlled asthma, use of
salbutamol rescue inhaler or unscheduled visits to
healthcare facilities for asthma, between children with
mild persistent asthma treated with paracetamol and
those with ibuprofen [58]. This trial did not address
whether the use of acetaminophen or ibuprofen, as
compared with no drug use, can worsen asthma [59].
Prevention of infective diseases is based on vaccina-
tions. Unfortunately, vaccinations are a painful proced-
ure. This pain may hamper their diffusion and may
cause short term side effects, including immunological,
endocrine, physiological and biochemical changes, and
long-term side effects, such as distress and negative ef-
fects on the development of the central nervous system.
Nowadays, various methods are used to reduce intensity
and duration of painful stimuli and make medical proce-
dures less painful. These include the injection technique,
such as not aspirating; physical interventions, like posi-
tioning the child upright or breastfeeding; pharmacologic
interventions, such as topical anesthetics and psycho-
logical interventions, like distraction techniques [60]. Flick
application was used to determine if pain level and dur-
ation of crying were reduced in a cohort of infants receiv-
ing hepatitis B vaccine injection. A significant difference
of pain score average was detected during and after the
application between intervention group and controls. No
difference was found on crying duration [61].
Breastfeeding may help reducing behavioral pain re-
sponses during vaccination compared to no treatment,
administration of water, and other interventions such as
cuddling, oral glucose, topical an aesthetic, massage, and
vapocoolants [62].
Henoch-Schönlein purpura (HSP) is a systemic leuko-
cytoplastic vasculitis characterized by IgA immune
deposits and represents the most common vasculitis in
childhood. Its etiology and pathogenesis remain un-
known, nevertheless several genetic, immunological and
environmental factors have been suggested as triggers.
Da Dalt et al. investigated retrospectively in a case-
control pediatric study the relation between drug or vac-
cine administration and HSP occurrence in 11 Italian
centers [63]. Measles-mump-rubella vaccine was associ-
ated with an increased risk for HSP. However, vaccinated
cases were only 8, suggesting a very low absolute risk of
the condition in children who received measles-mump-
rubella vaccine. No drug administration was associated
with HSP.
Neonatology. 1- Glucose monitoring; 2- salbutamol for
respiratory distress syndrome; 3 oxygen saturation;
4-antibiotic consumption
Several advances relating to hypo-glycemia, oxygen
treatment and antibiotic use in newborns have been
made last year. Maintenance of euglycemia is especially
challenging in the sick or low birth weight newborns.
Prompt treatment can prevent permanent damage and
promote intact survival. A continuous glucose monitor-
ing system (CGMS) can improve glucose control and de-
crease the frequency of blood samples taken from
newborns. In their study, Tiberi et al. [64] pointed to
clarify accuracy and safety of a new CGMS in preterm
infants using a Clarke error grid specifically modified for
this population. They collected data from 20 preterm in-
fants at increased risk for neonatal dysglycemia. The
CGMS sensor detects the interstitial glucose concentra-
tion every 10 s and transmits wirelessly it to the monitor
that calculates the average of glycemia every 5 min.
Values <40 mg/dl or >430 mg/dl cause an alarm sound
from the monitor. Authors’ findings confirmed a good
correlation between CGMS and finger-stick capillary
blood. Furthermore, the application of the sensor did
not lead to any interference with nursing care and in-
fants were not disturbed. Although the small population,
this study proved the efficacy of the CGMS that can be
used to quickly treat dysglycemia in preterm infants and
avoid undetected pathological glucose fluctuations.
Hegarty et al. [65] conducted a randomized, double-
blind, placebo-controlled study to determine whether 40%
dextrose gel prevents neonatal hypoglycemia and hence re-
duces admission to Neonatal Intensive Care Units (NICU)
in 416 babies at risk for hypoglycemia (preterm, diabetic
mother, small or large for gestational age). Authors found
that babies assigned to receive dextrose gel at any dose
were less likely to develop hypoglycemia than those who
received placebo. Gel was well tolerated and no babies
developed hyperglycemia. Admission to NICU for
hypoglycemia tended to be less common in babies
randomized to dextrose gel, but no difference was found
between dextrose and placebo groups. This study shows
that a single dose of 200 mg/kg (0.5 ml/kg) of dextrose is
effective and well-tolerated to reduce the incidence of neo-
natal hypoglycemia in babies born at risk. Harris et al. [66]
reported data of a two-years follow-up study in 184 chil-
dren who had been hypoglycemic (< 2.6 mM [45 mg/dL])
in the first 48 h of life and randomized to either dextrose
(90/118, 76%) or placebo gel (94/119, 79%) to determine
their neurodevelopmental outcome. All parents or
caregivers of babies enrolled in the previous study (the
Sugar Babies Study) [67] were invited to participate in
this follow-up study, of the 237 eligible babies assessed
previously, 184 (78%) were assessed at two years. Rates
of impairment were similar in both treatment groups
(dextrose 34/90 [38%] vs. placebo 32/94 [34%],
p = 0.60). No differences were observed in rate of neu-
rosensory impairment, processing difficulty, develop-
mental delayed and vision problems. Authors
demonstrated that the use of dextrose gel in treatment
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of hypoglycemia in neonatal period is not associated
with adverse effects at two years’ corrected age.
Neonatal respiratory distress syndrome (RDS) due to
surfactant deficiency is associated with high morbidity
and mortality in preterm infants. In addition, in
newborns with RDS there is an increase of lung fluid
content and secretion of fluid derived from the blood,
this contributes to respiratory distress. Lung airways
fluid absorption is mediated via Na+/K + −ATPase chan-
nel. β-agonists increase the Na channel activity mediated
by cAMP-PKA and lung sodium transport. Dehdashtian
et al. [68] investigated the efficacy of intratracheal salbu-
tamol administration in addition to surfactant in new-
borns with RDS. They assessed as primary outcome a
decrease of Intubation-Surfactant administration- Rapid
Extubation (INSURE) failure rate defined as the need for
reintubation and mechanical ventilation within 72 h of
extubation. They blindly randomized 48 newborns with
RDS to receive salbutamol (interventional group)
0.2 mg/kg or saline (control group) 0.5 ml/kg. Surfactant
was administered to the infants within 2 h of birth at
initial dose of 2.5 ml/kg and subsequent doses of 1.5 ml/
kg, according to the INSURE protocol. An INSURE
failure was found in 10 of 24 neonates in salbutamol
group compared to the 16 of 24 neonates in control
group (p = 0.082). Authors found that salbutamol ac-
companied by surfactant reduced duration of
hospitalization in newborns with RDS, but it did not
change duration of oxygen therapy, duration of NCPAP,
need of mechanical ventilation, mortality or other
complications.
High-flow therapy is a recent popular approach of
respiratory support in newborns. However, the evidence
of its efficacy and safety has not yet been established.
Roberts et al. [69] conducted an international, multicen-
ter, randomized, noninferiority trial, to assess the efficacy
of high-flow therapy as the primary respiratory support
for preterm infants with respiratory distress. They re-
cruited 515 infants born at a gestational age of 28 weeks
0 days to 36 weeks 6 days from nine NICU. After
reviewing the primary outcome data (treatment failure
within 72 h after randomization), the steering committee
stopped recruitment since high-flow treatment resulted
in a significantly higher rate of treatment failure than
CPAP when used as primary respiratory support for pre-
term infants at any gestational age (71/278 infants
(25.5%) in the high-flow group and 38/286 infants
(13.3%) in the CPAP group; p < 0.001). Authors
highlighted that high-flow therapy as first line respira-
tory support in preterm infants is not recommended.
Although oxygen is crucial for survival, too much
oxygen can be harmful. Monitoring and maintaining
optimal oxygen saturation (SpO2) by pulse oximetry is a
critical component of treating respiratory diseases.
Mascoll-Robertson et al. [70] determined whether the
histogram distribution of SpO2 over a 24-h period
predicts readiness for weaning respiratory support in
preterm infants. Their hypothesis was that infants
with > 15% of time spent with SpO2 < 86% before transi-
tioning from CPAP or high-flow nasal cannula (HFNC) to
low-flow nasal cannula, oxyhood, or room air are more
likely to fail transitioning. Thirty-five preterm infants with
gestational ages of 24–32 weeks were enrolled in this
prospective, observational cohort study. The histogram
distribution of pulse oximetry showing the percentage
of time spent in the preset oxygen saturation ranges
(96–100, 91–95, 86–90, 81–85, and < 80%) for a 24-h
period was recorded daily and the clinical team was
blinded to the 24-h histogram distributions. Overall, 7
of 31 subjects failed transition from CPAP/HFNC. In
the failure group, 2/7 (29%) subjects experienced
SpO2 < 86% ≥ 15% of the time before transitioning
compared with none in the successful group
(p = 0.045). The failure group experienced SpO2 < 86%
11 ± 12% of the time pre-wean compared with
3 ± 5% of time in the successful group (p = 0.02).
Conversely, infants in success group experienced a greater
percentage of time with SpO2 > 95% compared with the
failure group. These findings suggest that the combination
of pulse oximetry histogram and clinical stability criteria
can help clinicians to determine readiness for invasive
respiratory weaning, preventing transition failures.
Newborns are a population in which antibiotic con-
sumption is extremely high. Targeted antibiotic therapy
should help to reduce antibiotics consumption. Cantey et
al. [71] conducted a two-phases study, a retrospective
phase followed by an interventional phase to safely reduce
antibiotic use in the NICU. In the first months of the
study, all antibiotic use in infants admitted to the NICU
was recorded. During the intervention period, empirical
antibiotic therapy was set to discontinue after 48 h and
the duration of therapy for pneumonia and culture-
negative sepsis was limited to 5 days. A significant de-
crease in antibiotic consumption, defined as days of ther-
apy per 1000 patient-days, was found in the intervention
period in comparison with the baseline period (343.2 days
of therapy per 1000 patient-days at baseline vs 252.2 days
of therapy per 1000 patient-days during the intervention;
p < 0.0001). No difference in the proportion of infants
who were colonized with multidrug-resistant organisms
between baseline and intervention period was docu-
mented. There was no difference in the outcome of late-
onset sepsis, necrotizing enterocolitis, or death in infants
32 weeks’ gestation or younger in the baseline period
(17.1%) compared with the intervention period (15.8%).
The intervention resulted in both a 27% decrease in total
antibiotic use and a higher proportion of antibiotic use di-
rected at proven infection or necrotizing enterocolitis.
Caffarelli et al. Italian Journal of Pediatrics  (2017) 43:80 Page 9 of 16
These findings suggest that an overall increase in appro-
priate antibiotic administration in NICU can be designed
with close monitoring of patient safety outcomes.
Nephrology. Rituximab and antithrombotic prophylaxis in
nephrotic syndrome
Articles provided novel information on nephrotic syn-
drome, a common and important disorder characterized
by heavy proteinuria and hypoalbuminemia, usually as-
sociated with dyslipidemia and hypercoagulability [72].
International guidelines recommend a low-dose
alternate-day steroid regimen as first-line treatment for
the management of children with frequently-relapsing or
steroid-dependent nephrotic syndrome [73, 74]. Children
with nephrotic syndrome may have clinical relapses and/
or develop steroid dependence, this being defined as com-
plicated frequently relapsing/steroid-dependent nephrotic
syndrome. Resistance to steroids and all immunosuppres-
sive agents may also occur in a proportion of affected pa-
tients, and in these cases refractory steroid-resistant
nephrotic syndrome, a condition with substantial risk of
end-stage renal failure, has been described. Maratea et al.
[75] carried out an analysis aimed at assessing the efficacy
and safety of rituximab, a chimeric anti-CD20 monoclonal
antibody, for the treatment of children with nephrotic syn-
drome. The inclusion criteria of the studies were: a) a
study population of children with complicated frequently
relapsing/steroid-dependent nephrotic syndrome; b) the
choice of rituximab as treatment; c) the choice of steroids
and/or calcineurin inhibitors as control therapy; d)
complete remission rate as end-point. Four studies were
included in the meta-analysis, having as end-point the per-
centage of patients in remission at 6 months. The inter-
vention group consisted of patients treated with rituximab
plus prednisone and/or calcineurin inhibitors, while con-
trols were treated only with prednisone and/or calcineurin
inhibitors. The end-point was the percentage of patients
in remission at 6 months. Other end-points (e.g., relapse-
free survival rate for efficacy and adverse events for safety)
were also reported. Pooled data from these studies favored
the use of rituximab (RR 5.25; p < 0.0001). These results
were confirmed also at 12 months in two of the four stud-
ies. Moreover, children treated with rituximab had a lim-
ited number of adverse effects. Although more patients in
the rituximab group had serious adverse events (mainly
hypoproteinemia, lymphocytopenia and neutropenia)
compared to controls, the difference was not significant
(p = 0.36). The strength of this meta-analysis is that au-
thors include a total of 101 children from the four studies,
whereas other studies include an extremely limited study
population. The results of this meta-analysis confirm a
significant incremental benefit of adding rituximab to cor-
ticosteroid and/or calcineurin inhibitors for the treatment
of nephrotic syndrome.
Artoni et al. [76] described an adolescent with a
steroid-dependent nephrotic syndrome who experienced
a central vein thrombosis during the relapse of his base-
line disorder. Authors detected a severe inherited
thrombophilia (inherited dysfunctional protein S defi-
ciency) that was considered as an important additional
risk factors for thrombosis. Eventually, the patient
underwent a successful course of systemic thrombolysis
plus anticoagulant therapy. Venous thromboembolic
events are increasing in children because of therapeutic
advances in primary illnesses that previously caused
mortality (congenital heart disease, malignancy, trauma)
[77]. However, the estimated incidence of symptomatic
vein thrombosis in children is significantly less than that
in adults [78]. The etiology includes thrombophilia, head
and neck infections, and systemic illness. Among the ac-
quired prothrombotic disorders, nephrotic syndrome
may be complicated by thromboembolic events [79].
Thrombotic events during infancy and childhood are in-
creasingly recognized as a significant source of mortality
and morbidity. Thrombophilia can be defined as a pre-
disposition to form clots inappropriately. A hereditary
thrombophilia results when an inherited factor, such as
antithrombin or protein C deficiency, requires inter-
action with components that are inherited or acquired
before onset of a clinical disorder. In the presence of
ongoing risk factors, such as active nephrotic syndrome,
therapy should continue until the risk factor has re-
solved, but its optimal intensity is controversial.
Neurology. 1-Second generation antipsychotics;
2-Moebius syndrome. 3-Stroke; 4-migraine,
5-chromosomal imbalances in intellectual disability
The update by Pisano and co-workers concern about the
safety of second generation antipsychotic (SGA) drugs in
children and adolescents [80]. The manuscript was spe-
cifically focused on the studies published over a 5-years-
period that report the effect of SGA on a considerable
number of events or variables, i.e. body weight; abnor-
mal blood glucose levels, and elevated lipid levels; pro-
lactin concentration; and cardiometabolic and peripheric
or central nervous systems parameters. SGA did not be-
have as a homogeneous group in children and adoles-
cents with psychotic and mood disorders. Except for
clozapine, the heterogeneity within the SGA group was
mainly due to differences in the rates and severity of
adverse events, especially regarding weight gain as a
proxy for the risk of cardiometabolic disturbances [81].
Antipsychotic drugs block dopamine receptors and are
used to manage psychosis as well as other mental
illnesses that may or may not have psychotic features,
such as bipolar disorders and major depressive disorder.
First-generation antipsychotic drugs are more likely to
cause adverse effects such as extrapyramidal symptoms
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and tardive dyskinesia. Adverse effects of SGA drugs
typically were related to metabolic abnormalities such as
weight gain, abnormal blood glucose levels, and elevated
lipid levels. Neuroleptic malignant syndrome is a rare
but serious adverse effect of antipsychotic drugs that
causes mental status changes, hyperthermia, and gener-
alized rigidity. Timely diagnosis is essential due to a high
risk for related morbidities if the syndrome remains un-
treated. Some adverse effects of antipsychotics can be
identified and managed so that patients can continue
beneficial therapy while minimizing the physiologic
consequences. Patients taking antipsychotic drugs
should be monitored regularly for adverse effects.
Moebius syndrome (MBS) is a congenital, non-
progressive facial and abducens nerve palsy in the pres-
ence of full vertical gaze and may be associated with
limb abnormalities and craniofacial dysmorphisms. MBS
is now defined as a disorder of encephalic development
and recent gene discoveries have shown this to be a
dominant disorder in a subset of patients. Accurate diag-
nosis and management by a multidisciplinary team with
expertise in congenital facial palsy is paramount [82].
Picciolini and co-workers described a cohort of 50 MBS
patients aged from 1 month to 14 years from Italy [83].
All subjects had previously undergone a multidisciplin-
ary follow-up aimed at identifying the major complica-
tions which are associated to MBS. Findings from the
ophthalmological, neurological, audiological, orthopaedic
evaluation and from brain magnetic resonance imaging
were presented. Nutritional impairment was found in
16% of the cases as some patients were fed by nasogas-
tric tube until 1 year of age. A high proportion of cases
were found to have alteration of VII cranial nerve, but
normal intellectual quotient. Problems in language and
hearing caused hearing loss in approximately 7% of pa-
tients, language delay in 31%, speech deficit in 42%.
MBS is more than a cranial nerve or nuclear disorder
as lower brainstem involvement is described in affected
patients. The diagnosis of MBS may be difficult in some
patients with atypical signs of facial diplegia and other
cranial nerve palsies. Once diagnosed, patients with
MBS deserve a multidisciplinary follow-up [84].
Migraine and stroke are common events in the healthy
population. A link between them has been proposed
years ago, with various theories explaining it, but the
reason for the association remains unclear. Unfortu-
nately, migraine prophylaxis does not seem to decrease
the risk of stroke [85]. Nevertheless, subjects with major
cardiovascular risk factors should be encouraged to
adopt migraine prophylactic strategies. Spalice et al. [86]
briefly summarized the characteristics of the association,
provided a classification of migraine-related stroke, re-
ported on its pathogenesis and made recommendations
on the diagnostic pathway also in childhood. Migraine is
apparently a benign condition, while stroke remains an ex-
tremely common cause of disability, with a possible fatal
outcome. Both disorders have a high socioeconomic bur-
den. Migraine has been associated with both cardiac and
vascular disorders, most of all hypertension and myocar-
dial ischemic events, which may be complicated by stroke
[87, 88]. Spalice et al. [86] also focused on the fact that
genetic factors may play a role in the correlation between
migraine and stroke. We need further investigation to bet-
ter understand the complexity of migraine–stroke associ-
ation and to make firm recommendations for the future.
Array-CGH (aCGH) is used in current routine clinical
practice for diagnosis of patients with intellectual
disability (ID), multiple congenital anomalies (MCA),
and autism spectrum disorder (ASD) [89]. It can detect
small chromosomal imbalances, copy number variations
(CNVs), and can also closely define their size and gene
content [90]. The aims of Cappuccio’s study were to
establish clinical clues potentially associated with patho-
genic CNVs and to identify cytogenetic indicators to pre-
dict the pathogenicity of the variants of uncertain
significance in a cohort of 214 paediatric patients tested
with aCGH either as first-tier test or as part of a wider
diagnostic work-up. Pathologic findings were detected in
65 individuals (30%) and CNVs revealed the presence of
a known syndrome in 46 cases. The CNVs were most
frequently represented by deletions showing the highest
gene-dosage content. The presence of ASD and a
positive family history for ID, ASD and/or MCA were
clinical pointers for the suspicion of a pathological
chromosomal rearrangement together with eye anomal-
ies, hearing loss, neurological signs, cutaneous dyschro-
mia, and endocrinological disorders. Among patients
carrying variants of uncertain significance, a higher gene
density was found in patients affected by ID, suggesting
the possibility of a pathogenic gene involved and causing
ID in these patients. The detection of patients who are
most likely to have a diagnosis by aCGH, minimizing the
number of benign CNVs or negative results, remains an
attractive goal [91]. This study confirms the usefulness
of aCGH as first-tier test in patients with neurodevelop-
mental disorders. Furthermore, a diagnostic algorithm
for patients with unexplained ID and/or MCA and/or
ASD has been proposed.
Nutrition. Safety of donor milk and infant formula
New insights have been provided into the safety of milk
for infants. Holder pasteurization (HoP) is the most
widespread method for the treatment of donor milk
[92]. However, data from literature seem to suggest that
HoP may cause degradation of some bioactive compo-
nents [93, 94]. Peila et al. [95] carried out a study to
determine the effect of HoP on the protein profile of
human milk (HM) using the GeLC-MS method, a
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proteomic approach and a promising technique able to
offer a qualitative HM protein profile. The protein pro-
file before and after HoP showed qualitative differences
only in 6 samples out of 20. The differences interested
only colostrums and transitional milk samples and
regarded the decrease of the electrophoretic bands cor-
responding to alpha and beta-casein, tenascin, lactoferrin
and immunoglobulin. However, no significant differences
were observed after correction for delivery mode and/or
gestational age at birth. In the remaining 14 samples, no
detectable differences were found even after correction for
milk maturity degree. In most of, many of samples, HoP
did not cause any modification, thereby preserving the
biological activity of HM proteins. Future studies should
be designed to investigate whether the observed differ-
ences are also confirmed by other techniques able to as-
sess the protein changes due to thermic treatments
including the interaction between proteins and sugars, or
proteins and lipid, with possible toxic derivatives.
Powdered infant formulas (PIF) are generally not ster-
ile and are often contaminated by several bacteria strains
[96]. Among them, Cronobacter species, previously
known as Enterobacter sakazakii, is one of the most
harmful, since it might be the causative agent of sepsis
and meningitis in newborns and preterm infants during
the first weeks of life, with a mortality rate up to 80%
[97]. Therefore, some precautions are required in the
home handling and dilution of PIF. Although there is
wide consensus about the need that a PIF should be
used immediately after being diluted or, if not, stored at
<5 °C, the optimal temperature of the water used to di-
lute PIF is still debated by scientific societies and health
agencies. The current knowledge was reviewed in the
paper by Silano et al. [98] that provides evidence to cau-
tiously advise the use of hot water at a temperature of
70 °C in the dilution of PIF to prevent the Cronobacter
species contamination and growth. Research is currently
investigating methods to improve the microbiological
safety of PIF, via the inclusion of protectants or alterna-
tive methods to lower or eliminate microbiological con-
tamination. Among the most promising, bioactive
peptides, organic acids, probiotics and prebiotics should
be cited [99]. Supercritical carbon dioxide, gamma irradi-
ation, exposure to microwaves or to a combination of UV
and near infrared radiation heating are some among the
possible alternative physical methods. However, all these
recent technologies, though promising, still need further
investigation on safety, reproducibility and cost/benefit ra-
tio issues, before becoming standard procedures.
Pulmonology. 1-Bronchial secretion clearance; 2-recurrent
pneumonia
Management of secretions in children with cerebral
palsy is often problematic due to impaired cough, severe
deformation of the rib cage, and patients’ inability to
collaborate with chest physiotherapy [100]. While several
techniques allowing the management of airways secre-
tions in a comfortable, noninvasive mode exist, they are
nevertheless influenced by the patient’s cognitive status
and ability to cooperate [101]. An efficient drainage of
respiratory secretions through a “vacuum” effect has
been found to be effective and safe in adult patients, but
the effectiveness of such a treatment in children with
cerebral palsy is still under debate [102]. Assessing the
effectiveness of different methods and techniques of se-
cretion clearance is hampered by the lack of direct out-
come measures and by limited patient’s cooperation.
Garuti et al. [103] evaluated the efficacy of Free Aspire
in 8 patients with cerebral palsy who had experienced
more than 3 episodes of respiratory exacerbations in the
latest year despite therapeutic optimization (including
bronchial clearance techniques) and who had received at
least one antibiotic course or underwent at least one ac-
cess to the emergency room or admission to hospital in
the 6 months prior to the study. This Free Aspire device
uses Vakűm technology to remove secretions from the
bronchial tree in hyper secretive patients. During
expiration, the airflow is accelerated by the Venturi
effect inside a special connector, and the acceleration is
proportional to the flow of air on spontaneous breath-
ing, without requiring any cooperation. In the 6 months
prior to start the treatment, patients had a mean number
of 4.0 visits by the primary care pediatrician (PCP), spent
14 days in hospital, and received antibiotics for 35 days.
After the first 6 months of treatment, they had 1.7 PCP
visits, no days spent in hospital, and 9.75 days of anti-
biotic therapy. At 12 months of treatment, the number
of PCP visits, days in hospital, and days of antibiotics
were unchanged. At 18 months of treatment, no hospi-
talizations had occurred, PCP visits were 0.25, and days
of antibiotic therapy were 4.8. The technique proved to
be safe and well tolerated. The authors concluded that
the application of Free Aspire to improve the bronchial
secretion clearance in non-collaborating patients with
cerebral palsy is feasible and effective in reducing
respiratory complications and exacerbations, as well as
the utilization of healthcare resources (PCP visits, days
of hospitalization, need for antibiotics). Its regular use
maintains its efficacy over time. Randomized controlled
studies in larger patient cohorts on how to improve the
mucociliary clearance and thus optimize the respiratory
condition of children with cerebral palsy are required.
Recurrent pneumonia (RP) occurs in 6.7–8.2% of the
general pediatric population in industrialized countries,
is frequently described in association with a severe
underlying disease favoring lung infections, and is
considered a marker of the possible development of
non-cystic fibrosis bronchiectasis [103]. However, RP are
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often found in children without significant risk factors,
and this can delay the diagnosis of bronchiectasis, thus in-
creasing the risk of worsening lung function during ado-
lescence and adult life [104, 105]. The study by Patria et
al. [106] was designed to analyze the clinical records of 42
children with RP (21 with non-cystic fibrosis bronchiec-
tasis and 21 without non-cystic fibrosis bronchiectasis) to
identify factors that may lead to an early suspicion of
bronchiectasis, thus leading to prompt diagnosis and im-
plementation of the best prophylactic and therapeutic
measures. The most frequent underlying diseases in both
groups were chronic rhinosinusitis with post-nasal drip
and recurrent wheezing. FEV1 and FEF25–75 values were
significantly lower in children with bronchiectasis than in
those without. Bronchodilator responsiveness was ob-
served in seven children with bronchiectasis and two
without (p = 0.13). As reduced FEV1 and FEF25–75 values
seemed to be associated with an increased risk of develop-
ing bronchiectasis in children with RP, the authors sug-
gested the need for further studies to confirm the
diagnostic usefulness of spirometry in such cases.
Conclusions
Research in pediatrics was wide-ranging during this year.
This review summarizes new evidences about physiopa-
thology, diagnosis, prevention and treatment of common
diseases in childhood. Several scientific societies have
updated guidelines on various matters including fever,
atopic dermatitis, nephrotic syndrome, gastrointestinal
disorders, and hypertension. Overall, the management of
pediatric diseases has been improving to date towards a
patient’s tailored approach.
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